Lineage Cell Therapeutics (LCTX)
Develops off-the-shelf cell-replacement therapies for retinal, spinal-cord, hearing and corneal disease.
$0.9701
vs last close−0.07 (−6.72%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 1 | 1 | 4 | 3 | 2 | 3 | 4 | 7 | 2 | 1 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 2 | 1 | 1 | 4 | 3 | 1 | 3 | 4 | 7 | 2 | 1 |
| 8 | 8 | 7 | 8 | 8 | 8 | 23 | 7 | 13 | 9 | 10 | |
| Research & development | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 4 | 5 |
| 4 | 5 | 4 | 4 | 4 | 5 | 5 | 4 | 5 | 5 | 5 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 4 | 5 | 4 | 4 | 4 | 5 | 5 | 4 | 5 | 5 | 5 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | 0 | 0 |
| Operating income | −6 | −7 | −6 | −4 | −5 | −7 | −20 | −4 | −7 | −8 | −9 |
| 2 | 0 | 0 | 1 | 2 | 2 | −11 | −26 | 2 | 3 | 10 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −2 | 0 | 0 | −1 | −2 | −2 | −15 | 26 | −2 | −3 | −10 |
| Income before tax | −5 | −7 | −6 | −3 | −3 | −4 | −30 | −30 | −4 | −5 | 2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −5 | 0 | 0 |
| Net income from continuing operations | −5 | −7 | −6 | −3 | −3 | −4 | −30 | −30 | 1 | −5 | 2 |
| Net income | −5 | −7 | −6 | −3 | −3 | −4 | −30 | −30 | 1 | −5 | 1 |
| EPS, basic | −$0.03 | −$0.04 | −$0.03 | −$0.02 | −$0.02 | −$0.02 | −$0.13 | −$0.13 | $0.00 | −$0.02 | $0.01 |
| EPS, diluted | −$0.03 | −$0.04 | −$0.03 | −$0.02 | −$0.02 | −$0.02 | −$0.13 | −$0.13 | $0.00 | −$0.02 | $0.01 |
| Weighted average shares, basic | 173 | 183 | 189 | 189 | 200 | 226 | 228 | 229 | 230 | 245 | 249 |
| Weighted average shares, diluted | 173 | 183 | 189 | 189 | 200 | 226 | 228 | 229 | 230 | 261 | 261 |
| EBITDA | −5 | −6 | −6 | −3 | −3 | −4 | −5 | −30 | −4 | −5 | 2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −5 | −7 | −6 | −3 | −3 | −4 | −5 | −30 | −4 | −5 | 2 |